Drug Trial Radar · NCT06916897
A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Jan 8, 2025
Primary completion
Feb 22, 2025
Study completion Feb 22, 2025
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purposes of this Phase 1 study of sevasemten are to: 1. Evaluate the effect of multiple-dose administration of verapamil on the single-dose of sevasemten in healthy adults 2. Evaluate the safety and tolerability of a single dose of sevasemten administered with and without verapamil in healthy adult subjects. 3. Evaluate the safety and tolerability of a single dose of sevasemten administered with and without food in healthy adult subjects.
Conditions
- Healthy Subjects
Interventions
sevasemtenDrug
single dose 10mg sevasemten administered orally
VerapamilDrug
multiple doses 240mg verapamil
Primary outcomes
What the sponsor says the trial is designed to measure.
- PharmacokineticTime frame: Up to 46 days of monitoring
- PharmacokineticTime frame: Up to 46 days of monitoring
- PharmacokineticTime frame: up to 42 days of monitoring
- PharmacokineticTime frame: up to 42 days of monitoring
- PharmacokineticTime frame: up to 42 days of monitoring
- PharmacokineticTime frame: up to 42 days of monitoring
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.